Explore

Trendline Trendline
Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress

Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress

Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress
Trendline Trendline
Guided Therapeutics Inc Reports No Revenue and Increased Net Loss in Q1 2026

Guided Therapeutics Inc Reports No Revenue and Increased Net Loss in Q1 2026

Guided Therapeutics Inc Reports No Revenue and Increased Net Loss in Q1 2026
Trendline Trendline
Marker Therapeutics Reports Improved Financials Amidst Ongoing Clinical Developments

Marker Therapeutics Reports Improved Financials Amidst Ongoing Clinical Developments

Marker Therapeutics Reports Improved Financials Amidst Ongoing Clinical Developments
Trendline Trendline
Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026

Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026

Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026
Trendline Trendline
Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue

Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue

Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue
Trendline Trendline
Atossa Therapeutics Hosts Event on (Z)-Endoxifen for ER-Positive Breast Cancer

Atossa Therapeutics Hosts Event on (Z)-Endoxifen for ER-Positive Breast Cancer

Atossa Therapeutics Hosts Event on (Z)-Endoxifen for ER-Positive Breast Cancer
Trendline Trendline
Guided Therapeutics Reports Q1 2026 Financial Results Amid Regulatory Progress

Guided Therapeutics Reports Q1 2026 Financial Results Amid Regulatory Progress

Guided Therapeutics Reports Q1 2026 Financial Results Amid Regulatory Progress
Trendline Trendline
Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion

Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion

Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion
Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026

Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026

Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Trendline Trendline
Alpha Cognition Reports Q1 2026 Financial Results Highlighting Revenue Growth and Clinical Advancements

Alpha Cognition Reports Q1 2026 Financial Results Highlighting Revenue Growth and Clinical Advancements

Alpha Cognition Reports Q1 2026 Financial Results Highlighting Revenue Growth and Clinical Advancements
Trendline Trendline
Atisama Therapeutics Advances RB042 in Phase 1 Trial and Appoints New Board Chair

Atisama Therapeutics Advances RB042 in Phase 1 Trial and Appoints New Board Chair

Atisama Therapeutics Advances RB042 in Phase 1 Trial and Appoints New Board Chair
Trendline Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements